Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
NEREUS (tradipitant) is an oral small-molecule capsule approved by the FDA in December 2025 from Vanda Pharmaceuticals. The specific indication and mechanism of action are not yet disclosed in available data, limiting characterization at this stage. This represents a new chemical entity entering the market during its launch phase.
Early-stage launch with zero competitive pressure creates significant opportunity for field team expansion and commercial strategy development.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
Worked on NEREUS at Vanda Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moNEREUS is a newly approved product with zero current job postings, but launch status and competitive vacuum signal imminent hiring across commercial, medical, and field functions. This represents a ground-floor opportunity to build a brand team from inception and shape market positioning in an uncontested therapeutic space.